Skip to main content
Smart Investors Daily
Waters Corporation logo

NYSE · WAT

Waters Corporation

Healthcare · Medical - Diagnostics & Research

$456.48

Down-$11.40 (-2.50%)

Updated Nov 20, 2026, 3:27 PM

SID Score

6.5/10

Composite research score

Smart Money

58/100

Neutral

Market cap
23.37B
P/E ratio
36.01
Dividend yield
0.00%
52-week range
$282.77 – $483.33
Volume
1.02M
Avg. volume
656.11K

Price performance · WAT

WAT price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

WAT closed at $456.48 after 21 trading sessions, up 0.20% for the selected period.

Last close
$456.48
Period change
+0.20%
Period low
$449.53
Period high
$480.07
Daily close
View OHLC price history
WAT OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$469.17$471.98$454.96$456.481.02M
Nov 18, 2026$453.14$466.49$449.52$466.10734.16K
Nov 17, 2026$452.04$458.33$447.78$449.78585.02K
Nov 16, 2026$455.12$460.045$451.57$453.42575.43K
Nov 13, 2026$464.17$465.035$454.715$460.25521.85K
Nov 12, 2026$465.00$470.10$459.62$462.20557.85K
Nov 11, 2026$479.25$483.33$470.65$470.90651.95K
Nov 10, 2026$470.00$480.05$466.865$475.52889.33K
Nov 9, 2026$463.49$480.32$457.57$476.701.14M
Nov 6, 2026$450.61$463.905$450.61$457.60695.78K
Nov 5, 2026$465.66$466.37$451.795$453.081.15M
Nov 4, 2026$470.13$472.68$455.29$467.601.09M
Nov 3, 2026$456.61$474.36$449.51$459.901.79M
Nov 2, 2026$463.67$466.45$445.995$449.531.94M
Oct 30, 2026$479.04$480.63$458.85$462.721.34M
Oct 29, 2026$479.23$482.265$472.60$480.07883.05K
Oct 28, 2026$468.02$482.28$465.30$476.88872.59K
Oct 27, 2026$454.83$470.86$452.345$468.55797.39K
Oct 26, 2026$455.98$461.55$449.85$455.98909.15K
Oct 23, 2026$458.16$458.16$446.70$453.67907.61K
Oct 22, 2026$459.48$465.36$449.0875$455.591.27M

Latest WAT news

The latest Smart Investors Daily articles mentioning WAT.

WAT research

Overview

Company profile and research snapshot.

Company profile

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$409.67
Implied upside
—
Analysts
—
WAT recent ratings
DateFirmRatingTarget
Nov 4, 2026KeybancOverweight—
Nov 4, 2026CitigroupBuy—
Nov 4, 2026JP MorganNeutral—
Nov 4, 2026RBC CapitalOutperform—
Nov 4, 2026BarclaysOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Feb 25, 2026

Waters Merger With BD Unit Shifts Focus Toward Diagnostics And Valuation

Waters Corporation (NYSE:WAT) plans to merge with BD's life science and diagnostics business, targeting completion in early 2026. The transaction is expected to shift Waters' business mix toward diagnostics and life science tools. Shareholders are watching for how this combination could influence future revenue sources and competitive position. Waters, trading at around $326.3 per share, is approaching this planned merger after a period of mixed share performance. The stock is up 1.5% over...

Yahoo · Feb 24, 2026

What Makes Waters (WAT) a Strong Investment?

Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Mid Cap Fund”. A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise characteristics, with strong earnings trajectories, and are trading at a discount to the estimated private market value. US equities […]

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.